Page - 91 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Conniotet al. Nanocarriers for immunecell targetingand tracking Nanjwade, B. K., Bechra, H.M., Derkar, G. K., Manvi, F. V., andNanjwade, V. K. (2009). Dendrimers: emerging polymers for drug-delivery systems. Eur. J. Pharm.Sci.38,185–196.doi:10.1016/j.ejps.2009.07.008 Naumova, A. V., Modo, M., Moore, A., Murry, C. E., and Frank, J. A. (2014). Clinical imaging in regenerativemedicine.Nat. Biotechnol. 32, 804–818. doi: 10.1038/nbt.2993 Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., and Couvreur, P. (2013). Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem.Soc.Rev.42,1147–1235.doi:10.1039/c2cs35265f Niederhafner, P., Reinis,M., Sebestik, J., and Jezek, J. (2008). Glycopeptide den- drimers, part III: a review. Use of glycopeptide dendrimers in immunother- apy and diagnosis of cancer and viral diseases. J. Pept. Sci. 14, 556–587. doi: 10.1002/psc.1011 Niino,D.,Komohara,Y.,Murayama,T.,Aoki,R.,Kimura,Y.,Hashikawa,K., et al. (2010). Ratio of M2macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol. Int. 60, 278–283.doi:10.1111/j.1440-1827.2010.02514.x Oble,D.A.,Loewe,R.,Yu,P.,andMihm,M.C.Jr. (2009).FocusonTILs:prognos- tic significanceof tumor infiltrating lymphocytes inhumanmelanoma.Cancer Immun.9,3. Ocampo-Garcia, B., Ferro-Flores, G., Morales-Avila, E., and Ramirez Fde, M. (2011). Kit for preparation of multimeric receptor-specific (9)(9)mTc- radiopharmaceuticals based on gold nanoparticles.Nucl. Med. Commun. 32, 1095–1104.doi:10.1097/MNM.0b013e32834acf33 Osaki, M., Kase, S., Adachi, K., Takeda, A., Hashimoto, K., and Ito, H. (2004). Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas- mediated apoptosis in human gastric carcinoma cell line,MKN-45. J. Cancer Res.Clin.Oncol.130,8–14.doi:10.1007/s00432-003-0505-z Ostrand-Rosenberg, S. (2004).Animalmodels of tumor immunity, immunother- apyandcancer vaccines.Curr.Opin. Immunol.16, 143–150.doi: 10.1016/j.coi. 2004.01.003 Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., et al. (1998). Vascularendothelialgrowthfactoraffectsdendriticcellmaturationthroughthe inhibitionofnuclear factor-kappaBactivation inhemopoieticprogenitorcells. J. Immunol.160,1224–1232. Palucka,K., andBanchereau, J. (2012).Cancer immunotherapyviadendritic cells. Nat.Rev.Cancer12,265–277.doi:10.1038/nrc3258 Pan,J.,andFeng,S.S. (2008).Targeteddeliveryofpaclitaxelusingfolate-decorated poly(lactide)-vitamin ETPGSnanoparticles.Biomaterials 29, 2663–2672. doi: 10.1016/j.biomaterials.2008.02.020 Panyam, J., and Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue.Adv. Drug Deliv. Rev. 55, 329–347. doi: 10.1016/S0169-409X(02)00228-4 Park, J.H.,VonMaltzahn,G.,Zhang, L.,Derfus,A.M., Simberg,D.,Harris, T. J., etal. (2009).Systematicsurfaceengineeringofmagneticnanowormsfor invivo tumortargeting.Small5,694–700.doi:10.1002/smll.200801789 Partlow,K.C.,Chen,J.,Brant,J.A.,Neubauer,A.M.,Meyerrose,T.E.,Creer,M.H., etal. (2007).19Fmagnetic resonance imaging for stem/progenitorcell tracking withmultiple unique perfluorocarbonnanobeacons.FASEB J. 21, 1647–1654. doi:10.1096/fj.06-6505com Patel, S. K., Zhang, Y., Pollock, J. A., and Janjic, J. M. (2013). Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions- invitro study.PLoSONE8:e55802.doi:10.1371/journal.pone.0055802 Pedroza-Gonzalez,A.,Xu,K.,Wu,T.C.,Aspord,C., Tindle, S.,Marches, F., et al. (2011).Thymic stromal lymphopoietin fostershumanbreast tumorgrowthby promoting type 2 inflammation. J. Exp.Med. 208, 479–490. doi: 10.1084/jem. 20102131 Peer,D.,Karp,J.M.,Hong,S.,Farokhzad,O.C.,Margalit,R.,andLanger,R.(2007). Nanocarriers as an emergingplatform for cancer therapy.Nat.Nanotechnol.2, 751–760.doi:10.1038/nnano.2007.387 Pejawar-Gaddy, S., Rajawat, Y., Hilioti, Z., Xue, J., Gaddy, D. F., Finn, O. J., et al. (2010). Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol. Immunother.59,1685–1696.doi:10.1007/s00262-010-0895-0 Pelkmans,L.,andHelenius,A.(2002).Endocytosisviacaveolae.Traffic3,311–320. doi:10.1034/j.1600-0854.2002.30501.x Peng, G.,Wang,H. Y., Peng,W., Kiniwa, Y., Seo, K.H., andWang, R. F. (2007). Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity27,334–348.doi:10.1016/j.immuni.2007.05.020 Poulose, A. C., Veeranarayanan, S., Mohamed,M. S., Raveendran, S., Nagaoka, Y.,Yoshida,Y., et al. (2012).PEGcoatedbiocompatible cadmiumchalcogenide quantumdots for targeted imagingofcancercells. J.Fluoresc.22,931–944.doi: 10.1007/s10895-011-1032-y Progatzky, F., Dallman, M. J., and Lo Celso, C. (2013). From seeing to believ- ing: labelling strategies for in vivo cell-tracking experiments. Interface Focus 3, 20130001.doi:10.1098/rsfs.2013.0001 Prokop, A., and Davidson, J. M. (2008). Nanovehicular intracellular delivery systems. J.Pharm.Sci.97,3518–3590.doi:10.1002/jps.21270 Psimadas,D.,Baldi,G.,Ravagli,C.,Bouziotis, P.,Xanthopoulos, S., Franchini,M. C.,etal. (2012).Preliminaryevaluationofa99mTclabeledhybridnanoparticle bearing a cobalt ferrite core: in vivobiodistribution. J. Biomed.Nanotechnol.8, 575–585.doi:10.1166/jbn.2012.1412 Raaijmakers, M. I., Rozati, S., Goldinger, S. M., Widmer, D. S., Dummer, R., andLevesque,M.P. (2013).Melanoma immunotherapy: historical precedents, recentsuccessesandfutureprospects. Immunotherapy5,169–182.doi:10.2217/ imt.12.162 Rabin,O.,ManuelPerez, J.,Grimm,J.,Wojtkiewicz,G., andWeissleder,R. (2006). An X-ray computed tomography imaging agent based on long-circulating bismuthsulphidenanoparticles.Nat.Mater.5,118–122.doi:10.1038/nmat1571 Radford,K. J., andCaminschi, I. (2013).Newgenerationofdendriticcell vaccines. Hum.Vaccin. Immunother.9,259–264. Rahir, G., and Moser, M. (2012). Tumor microenvironment and lymphocyte infiltration.Cancer Immunol. Immunother. 61, 751–759. doi: 10.1007/s00262- 012-1253-1 Rawat,M.,Singh,D.,Saraf,S.,andSaraf,S.(2006).Nanocarriers:promisingvehicle forbioactivedrugs.Biol.Pharm.Bull.29,1790–1798.doi:10.1248/bpb.29.1790 Reddy,G.R., Bhojani,M. S.,McConville, P.,Moody, J.,Moffat, B.A.,Hall,D. E., etal. (2006).Vasculartargetednanoparticles forimagingandtreatmentofbrain tumors.Clin.CancerRes.12,6677–6686.doi:10.1158/1078-0432.CCR-06-0946 Reimer, P., and Balzer, T. (2003). Ferucarbotran (Resovist): a new clinically approvedRES-specific contrast agent for contrast-enhancedMRI of the liver: properties, clinical development, andapplications.Eur.Radiol.13, 1266–1276. doi:10.1007/s00330-002-1721-7 Riehemann,K.,Schneider,S.W.,Luger,T.A.,Godin,B.,Ferrari,M.,andFuchs,H. (2009).Nanomedicine–challenge andperspectives.Angew.Chem. Int. EdEngl. 48,872–897.doi:10.1002/anie.200802585 Rizvi, S. B., Rouhi, S., Taniguchi, S., Yang, S. Y., Green,M., Keshtgar,M., et al. (2014). Near-infrared quantum dots for HER2 localization and imaging of cancercells. Int. J.Nanomedicine9,1323–1337.doi:10.2147/IJN.S51535 Rohani, R., De Chickera, S. N., Willert, C., Chen, Y., Dekaban, G. A., and Foster, P. J. (2011). In vivo cellular MRI of dendritic cell migration using micrometer-sized ironoxide (MPIO)particles.Mol. ImagingBiol.13,679–694. doi:10.1007/s11307-010-0403-0 Roitt, I.M.,andDelves,P.J. (2001).Roitt’sEssential Immunology.Oxford:Blackwell Science. Romani,N.,Gruner, S.,Brang,D.,Kampgen,E.,Lenz,A.,Trockenbacher,B., et al. (1994). Proliferating dendritic cell progenitors in human blood. J. Exp.Med. 180,83–93. Rosenberg, S. A. (2001). Progress in human tumour immunology and immunotherapy.Nature411,380–384.doi:10.1038/35077246 Rosenberg, S. A., Yang, J. C., and Restifo, N. P. (2004). Cancer immunotherapy: movingbeyondcurrentvaccines.Nat.Med.10,909–915.doi:10.1038/nm1100 Rosenberg, S.A.,Yang, J.C., Sherry,R.M.,Kammula,U. S.,Hughes,M.S., Phan, G.Q., et al. (2011).Durable complete responses inheavily pretreatedpatients withmetastaticmelanomausingT-cell transfer immunotherapy.Clin. Cancer Res.17,4550–4557.doi:10.1158/1078-0432.CCR-11-0116 Ruan,G.,Agrawal,A.,Marcus,A.I.,andNie,S.(2007). Imagingandtrackingoftat peptide-conjugated quantumdots in living cells: new insights into nanoparti- cleuptake, intracellular transport, andvesicle shedding. J.Am.Chem.Soc.129, 14759–14766.doi:10.1021/ja074936k Sahoo, S. K., and Labhasetwar, V. (2003). Nanotech approaches to drug delivery and imaging.DrugDiscov. Today 8, 1112–1120. doi: 10.1016/S1359-6446(03) 02903-9 Santra, S., Dutta, D., Walter, G. A., and Moudgil, B. M. (2005). Fluorescent nanoparticleprobes forcancer imaging.Technol.CancerRes.Treat.4,593–602. doi:10.1177/153303460500400603 Frontiers inChemistry | ChemicalEngineering November2014 |Volume2 |Article105 | 91